Morgan Stanley downgraded AKAM stock's rating to "underweight" from "equal weight," and also slashed its price target by $14 to $54. The bearish note hits ahead of the company's earnings report, due after the close next Tuesday. On the …
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal – making it the fifth-largest biotech deal in history …
Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on …
"But giving the way the stock is reacting, maybe we're coming close to finding a bottom here." In the technology sector, Brady said Nokia has good fundamentals, so he's inclined to hold onto Nokia. He also said Amgen is a terrific company …
A federal judge rejected Amgen Inc.'s effort to temporarily block a competitor from releasing a copycat version of one of its top-selling biologic drugs. The Thousand Oaks biotech company had accused Novartis subsidiary Sandoz of violating …
By Mr. Loeb’s reckoning, a breakup could yield significant results. Given its current corporate self-help plan, Amgen appears set to improve its stock’s valuation to $189 a share by the end of 2016. But if the company splits itself in two, …